Fargo, ND , June 2 2022 – RxE2 announces the appointment of David Stark as Senior Director of Business Development.
In his role as senior director of business development, Mr. stark will be in charge of exploring new opportunities for expansion and partnerships for RxE2.
“We were looking for an individual with a wide range of clinical experience who could think outside the box while embodying the values of RxE2, especially as RxE2 incorporates the practice of pharmacy into clinical research”, says Gerald Finken, CEO of RxE2. “ We found that person in David. His years of experience and understanding of our industry fit our needs perfectly, but it is his passion for his work that truly sets him apart. We are thrilled to welcome David to our team”.
Mr. Stark is a 27-year veteran of the clinical research industry. From a CRA I to VP of clinical both Pharma and medical device. He is a multi-award-winning business development executive (preclinical, clinical Phase I-3, clinical systems, and Biometrics) with a track record of revenue, market share, and customer growth in competitive marketplaces and a background in all levels of clinical study management. A proven strategist and sales hunter with a history of formulating, communicating and operationalizing impactful sales plans, expansion roadmaps, and growth targets to drive business from new and existing accounts.
“What do you need to be successful in the clinical research industry? Three simple things: know your product better than anyone, know your sponsor, and have a burning desire to succeed. RxE2 has a deep understanding of the sponsors’ needs, and our team has the passion for bringing it to them. I am excited take part in this journey”, said Mr. Stark.
About RxE2
RxE2 is the first company to make community-based decentralized clinical trials a cost-effective reality. By integrating the practice of pharmacy into every aspect of clinical trials, RxE2 empowers community pharmacists, as trusted medication experts, to use their extensive patient insights to make clinical trials more accessible for everyone, everywhere, to vastly reduce clinical trial timelines and costs, and to help study sponsors and patients alike achieve higher quality outcomes.
